What if you could correctly predict — nine times out of ten — that your drug will have the intended efficacy in a clinical trial?

Our unique discovery platform can do that. By isolating the tumor-causing biology and testing it against the full spectrum of a drug's effects in a biological system, we precisely match drugs to patients that could benefit. With 95% of all cancer patients represented and a screening throughput of hundreds of drugs per week, we enable precision oncology at scale.

Applications include patient selection for pre-clinical assets, identifying repurposing opportunities into oncology, prioritizing additional indications for already marketed drugs, and many others. We are especially focused on identifying treatment opportunities for underexplored and challenging cancer types where the unmet clinical need is most profound.